Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 7/20 | 0.38 |
| ▸ | ACHE | P22303 | 7/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5319030 | 0.98 | MAPK1 (0.40) | RXFP1MAPK1CSF1RBCHEACHE | |
| SCHEMBL3861888 | 0.93 | MAPK1 (0.41) | RXFP1MAPK1CSF1RBCHEACHE | |
| SCHEMBL3169059 | 0.84 | POLB (0.43) | RXFP1MAPK1CSF1RCYP1A2CYP3A4 | |
| SCHEMBL3861875 | 0.84 | CYP1A2 (0.42) | RXFP1MAPK1CSF1RBCHEACHE | |
| SCHEMBL6219586 | 0.83 | MAPK1 (0.40) | RXFP1MAPK1CSF1RBCHEACHE | |
| SCHEMBL1950078 | 0.83 | POLB (0.46) | BCHEACHEGAAKDM4EALDH1A1 | |
| SCHEMBL3862617 | 0.83 | EGFR (0.41) | RXFP1CSF1RCYP1A2CYP2D6HDAC3 | |
| SCHEMBL3868941 | 0.82 | MAPT (0.43) | RXFP1MAPK1BCHEACHEGAA | |
| SCHEMBL3868943 | 0.82 | MAPT (0.43) | RXFP1MAPK1BCHEACHEGAA | |
| SCHEMBL203808 | 0.82 | STK17B (0.44) | MAPK1BCHEACHECYP2D6EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598382-B2 | Aryl substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-25 | — | — | US | disclosed |
| EP-1590348-A1 | ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20040147543-A1 | Aryl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-29 | — | — | US | disclosed |
| WO-2004058759-A1 | ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147543-A1 | Aryl substituted imidazoquinolines | IL2, IFNG, IRF3 | RXFP1 3990/4885MAPK1 2202/4885CSF1R 294/4885 |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | RXFP1 3990/4885MAPK1 2202/4885CSF1R 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.